The *Nkx2.3–Nr5a1* gene cascade plays a crucial role in spleen-specific vascular

architecture and marginal zone formation

Kanako Miyabayashi[1*], Koji Ono[2*†], Tetsuya Sato[3], Ayano Yahagi[4§], Masanori Iseki[4],

Katsuhiko Ishihara[4¶], Takami Mori[5‡], Miki Inoue[1], Ryuki Shimada[6], Kei-ichiro Ishiguro[7],

Tomohiro Ishii[8], Jongsung Noh[9], Man Ho Choi[9], Takashi Baba[10], Yasuyuki Ohkawa[11], Emi

Kiyokage[5], Kazunori Toida[2], Yuichi Shima[1]

[1]Division of Microscopic and Developmetal Anatomy, Department of Anatomy, Kurume

University, School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan

[2]Department of Anatomy, Kawasaki Medical School,

577 Matsushima, Kurashiki, Okayama 701-0192, Japan

[3]Biomedical Research Center, Faculty of Medicine, Saitama Medical University, 1397-1

Yamane, Hidaka, Saitama 350-1241, Japan

[4]Department of Immunology and Molecular Genetics, Kawasaki Medical School,

577 Matsushima, Kurashiki, Okayama 701-0192, Japan

[5]Department of Medical Technology, Kawasaki University of Medical Welfare, 288

Matsushima, Kurashiki, Okayama 701-0193, Japan

[6]Department of Chromosome Biology, Institute of Molecular Embryplogy and Genetics

(IMEG), Kumamoto University, Kumamoto, Japan

[7]Department of Biomedical Science, Graduate School of Medicine, Chiba University, 260-8670,

Japan

[8]Department ot Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan

[9]Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology,

Seoul, Korea

[10]Department of Molecular Biology, Graduate School of Medical Sciences, Kyushu University,

Fukuoka, Japan

[11]Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka,

Japan

[*]These authors equally contributed to the work

[†]Present address: Faculty of Health and Medical Care, School of Medical Technology, Saitama

Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1241, Japan

§Present address: Department of Microscopic Anatomy and Developmental Biology, Tokyo

Women's Medical University, 8-1, Kawada-cho, Tokyo 112-8681, Japan

¶Present address: Department of Design for Medical and Health Care, Faculty of Health and

Welfare Services Administration, Kawasaki University of Medical Welfare, 288 Matsushima,

Kurashiki, Okayama 701-0193, Japan

‡Present address: Department of Clinical Laboratory, Saga University Hospital, 5-1-1

Nabeshima, Saga 849-8501, Japan

Corresponding author: Yuichi Shima, M.D., Ph.D.

Division of Microscopic and Developmetal Anatomy, Department of Anatomy, Kurume

University, School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka 830-0011, Japan

Tel: +81 942 35 3311 (ext. 3150)

e-mail: yshima@kurume-u.ac.jp

Grants: This work was supported by JSPS (Japan Society for the Promotion of Science)

KAKENHI Grant numbers 19K07378 (Y.S.), 23K19458, and 24K09992 (K.M.); Ryobi Teien

Memory Foundation (Y.S.); Wesco Scientific Promotion Foundation (Y.S.); Research Project

Grant from Kawasaki Medical School (R01B to K.O. and Y.S.); Startup Award for Researchers

with Life Events at Kurume University (K.M.); and Grant from Kurume University for the

Promotion of female researcher (K.M.).

Abstract

NR5A1 is a nuclear receptor and master regulator of steroidogenic tissue development and steroid hormone biosynthesis in the adrenal glands and gonads. While NR5A1 is expressed in splenic vascular endothelial cells, its functional role in the adult spleen remains poorly understood. Using single-cell transcriptomics in mice, here, we showed that NR5A1-positive endothelial cells were heterogeneous, with distinct phenotypes tied to their location in the splenic sinus versus the marginal sinus. To determine its function, we generated a spleen-specific *Nr5a1* enhancer deletion model. Loss of the enhancer led to reduced spleen size and ablation of both the marginal zone and marginal sinus. Moreover, 21α-hydroxylase activity in splenic sinusoidal endothelial cells was markedly diminished—especially in females—resulting in lower levels of adrenocortical steroids in the spleen. Enhancer deletion also induced ectopic lymphatic-like and high endothelial venule-like vasculature. These "lymph node–like" structures mirror those seen in *Nkx2.3*-deficient mice, and mutation of the NKX2.3-binding motif within the enhancer completely abolished NR5A1 expression in the spleen. These results together reveal that an *Nkx2.3→Nr5a1* regulatory axis is essential for the morphological and functional differentiation of spleen-specific vascular endothelial cells, with implications for splenic architecture necessary for blood filtration and marginal zone formation.

Key words:

NR5A1, enhancer, spleen, red pulp, white pulp, splenic sinus, marginal sinus, marginal zone, lymphocytes, erythrocytes, macrophage

Introduction

The spleen is a major secondary lymphoid organ that integrates blood filtration with immune surveillance. Structurally, it is composed of red and white pulp. Blood entering the spleen is directed either into the red pulp or into the marginal sinus located at the interface between the red and white pulp. In the red pulp, erythrocytes exiting the central arteries enter the open circulation and subsequently re-enter the lumen of splenic sinuses through interendothelial slits between elongated sinusoidal endothelial cells[1]. This unique vascular organization functions as a blood filter, in which aged or inflexible erythrocytes are retained and phagocytosed by macrophages[2]. Meanwhile, the marginal sinus and the surrounding marginal zone constitute a specialized vascular niche that regulates cellular trafficking into the white pulp[3]. Several immune cell populations, including SIGNR1 (CD209b)-positive macrophages, macrophage receptor with a collagenous structure (MARCO)-positive marginal zone macrophages[4,5], CD169 (SIGLEC-1/sialoadhesin)-positive marginal zone metallophilic macrophages[6,7], and marginal zone B cells[8], reside in the marginal zone and contribute to immune surveillance of blood-borne antigens[9-11].

NR5A1 (also known as Ad4BP or steroidogenic factor-1) is a nuclear receptor essential for the development and function of steroidogenic tissues, including the adrenal glands and gonads[12]. NR5A1 is also expressed in splenic sinusoidal endothelial cells, and mice lacking *Nr5a1* exhibit markedly reduced spleen size during fetal development[13]. However, interpretation of these findings has been limited by early postnatal lethality due to adrenal insufficiency[14], leaving the role of NR5A1 in the adult spleen unresolved. Recent single-cell transcriptomic studies have shown that genes involved in steroid hormone biosynthesis are selectively expressed in splenic endothelial cells[15]. Although NR5A1 directly regulates steroidogenic enzyme expression in the adrenal cortex[16], whether NR5A1 controls steroidogenic programs or other specialized functions in splenic endothelial cells remains unknown.

NKX2.3 is a homeobox transcription factor that plays a crucial role in the formation of splenic venous sinuses. *Nkx2.3* (*Nkx2-3*) knockout mice exhibit defects in the spleen and gut-associated lymphoid tissues[17]. In particular, the marginal zone is severely disrupted in *Nkx2.3*-deficient spleens[18,19], and lymphoid cysts filled with lymphocytes and high endothelial venules (HEVs)—structures normally restricted to lymph nodes—develop in knockout spleens[20,21].

In this study, we combine single-cell transcriptomics with genetic perturbation to define the role of NR5A1 in splenic vascular endothelial cells. We show that NR5A1-positive endothelial cells comprise transcriptionally distinct populations within the splenic and marginal

sinuses and identify a spleen-specific enhancer that governs *Nr5a1* expression in these

compartments. Functional disruption of this enhancer reveals that endothelial NR5A1 is

indispensable for establishing spleen-specific vascular identity, marginal sinus formation, and

marginal zone organization. Furthermore, we demonstrate that NKX2.3 directly regulates this

enhancer, thereby defining an *Nkx2.3–Nr5a1* transcriptional axis that plays a crucial role in

establishing vascular identity and functional architecture in the spleen.

Materials and Methods

Mouse strains

Ad4BP-BAC-EGFP mice[22] were used to visualize NR5A1-expressing sinus endothelial cells

and to isolate NR5A1-positive cells. StAR/eGFP mice have been described previously[23]. ΔSpE

mice were generated using genome editing[24-26]. Guide RNAs flanking the SpE were designed

using CRISPR Direct (http://crispr.dbcls.jp/), and crRNA, tracrRNA, and Cas9 protein

(Integrated DNA Technologies) were mixed and introduced into fertilized eggs by

electroporation (Genome Editor, BEX). For SpE-R2m mice, a guide RNA targeting the R2

sequence and donor DNA carrying a mutated R2 sequence (R2m) were used. Edited embryos

were transferred into recipient oviducts, and the genotypes were determined by PCR, with R2m

integration confirmed by *Bam*HI digestion. Guide RNA and genotyping primer are provided in

Supplemental Table 1. All animal experiments were approved by the Animal Care and Use

Committee of Kawasaki Medical School and Kurume University School of Medicine.

Single-cell transcriptome analyses of NR5A1$^+$ endothelial cells

Ad4BP-BAC-EGFP mice were sacrificed at approximately P70, and spleens were collected (n =

3; 2 males and 1 female). Spleens were minced, digested with collagenase (Nacalai Tesque),

and EGFP-positive cells were isolated by fluorescence-activated cell sorting (FACS) using BD

FACSAria III (BD) or CytoFLEX SRT (Agilent Biotechnologies). Sorted cells were processed

for scRNA-seq using the 10x Genomics Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,

following the manufacturer's protocol, and libraries were sequenced on an Illumina NovaSeq

6000.

FASTQ files were processed with Cell Ranger (v9.0.0) using default settings and

aligned to a custom reference genome generated by appending the EGFP cDNA sequence to

mm10. Feature-barcode matrices were generated using the "count" pipeline. Subsequent

analyses were performed in R using Seurat (v5.1.0)[27]. Cells with < 500 detected genes, > 6,000

UMIs, or > 10% mitochondrial reads were excluded. Doublets were removed using

DoubletFinder (v2.0.6)[28], assuming a 7.5% of doublet rate and an optimal pK value determined

by "find.pK". After quality filtering, including the EGFP expression, 31,199 cells were retained

across three batches.

Gene expression data were normalized using "NormalizeData", and batch effects

were corrected and integrated using Harmony[29]. Dimensionality reduction was performed by

PCA, and the top 30 principal components were used for clustering with the Louvain algorithm

at a resolution of 0.1 using "FindClusters". Clusters were visualized by UMAP using

"RunUMAP". Differentially expressed genes (DEGs) were identified using "FindAllMarkers"

with the Wilcoxon rank-sum test and Bonferroni correction. Marker genes were defined as those

with an average log2 fold change ≥ 1 and an adjusted p-value < 0.01.

Functional annotation of cluster-specific markers was performed by Gene Ontology

(GO) enrichment analysis using clusterProfiler (v 4.17.0)[30]. For each cluster, the top 150 DEGs

ranked by log2 fold-change were analyzed using "compareCluster" and "enrichGO" with a q-

value cutoff of 0.01, across biological processes (BP), molecular functions (MF), and cellular

components (CC) categories.

Western blot analyses

Nuclear extracts were prepared from adrenal glands and spleens (Nuclear Extraction Kit,

ab113474, Abcam) and quantified using a Qubit Protein Assay (Thermo Fisher Scientific).

Forty micrograms of protein was subjected to SDS-polyacrylamide gel electrophoresis and

western blot. Primary and secondary antibodies are listed in Supplemental Table 2.

Tissue preparation, histological studies, and immunostaining

Mice were anesthetized with medetomidine hydrochloride (0.3 mg/kg; Nippon Zenyaku

Kogyo), midazolam (4 mg/kg; Astellas Pharma), and butorphanol tartrate (5 mg/kg; Meiji Seika

Pharma). Fresh tissues were collected, and bright-field or fluorescence images were acquired

using a stereomicroscope (Evident SZx10 or SZX16). For histology, mice were perfused with

PBS followed by 4% paraformaldehyde (PFA) in PBS, and tissues were further fixed by

immersion in 4% PFA.

Paraffin-embedded tissues were sectioned at 5 μm and stained with hematoxylin and

eosin (H&E). Images were acquired using a BZ-X700 (Keyence) and used to quantify white

pulp and total spleen areas with MZ-X Analyzer 1.3.0.3 (Keyence). For immunostaining, tissues

were sectioned at 50 μm using a CM3050 S cryotome (Leica) and stained by the free-floating

method[26]. Antibodies are listed in Supplemental Table 2. Nuclei were counterstained with DAPI

(Sigma), sections were mounted in VECTASHIELD (Vector Laboratories), and images were

acquired using a BZ-X700 (Keyence) or LSM 700 laser-scanning microscope (Zeiss).

Analyses of the circulating hemocytes

Blood smear samples were stained with Giemsa, and erythrocytes containing Howell–Jolly

bodies was counted using a BX61 microscope equipped with a DP74 camera (Olympus). At

least 1,000 erythrocytes were analyzed per specimen (n = 4 per group).

Scanning electron microscopic (SEM) studies

Spleens were fixed by interstitial perfusion[31] and immersion in 2.5% glutaraldehyde (TAAB)

and 4% PFA (Merck) in 0.1 M phosphate buffer (pH 7.4). Tissues were trimmed, post-fixed

with 1% OsO_4, incubated in 50% DMSO, freeze-fractured in liquid nitrogen, and post-fixed

again with 1% OsO_4. Specimens were treated with 2% tannic acid for 16 h and 2% OsO_4 for 6 h

using the tannin-osmium method[32], dehydrated through graded ethanol, transferred to *t*-butyl

alcohol, and freeze-dried. Fractured surfaces were mounted on metal stubs, coated with osmium

and platinum, and examined using an S-3400N scanning electron microscope (Hitachi) at 15

kV.

Bulk mRNA-sequencing, data processing, and differential gene expression analyses

Bulk mRNA-seq was performed as previously described[25,26]. Total RNA from spleens or

endothelial cells sorted from Ad4BP-BAC-EGFP spleens was used for library preparation with

Illumina TruSeq (Illumina) or NEBNext Ultra RNA Library Prep Kit (New England Biolabs).

Libraries were sequenced on a NovaSeq 6000 with 150-bp paired-end reads. After adapter and

low-quality sequences removal using Cutadapt, reads were aligned to mm10 using STAR

(v2.7.3a). FeatureCounts (v2.0.1) and edgeR (v3.28.1) were used to calculate counts per million

(CPM). DEGs were identified using the criteria of $|Log2FC| \geq 2$, $p < 0.01$, and FDR < 0.01, and

were subjected to GO analyses using Metascape[33]

(https://metascape.org/gp/index.html#/main/step1).

Flow cytometry analyses

Flow cytometry of splenic immune cells was performed as previously described[34]. Antibodies

used for the analyses are listed in Supplemental Table 2.

Measurement of steroid hormones in the spleen

Spleens were collected from control and △SpE mice at approximately 10 weeks after birth (n =

3 per group). Steroid levels were determined by liquid chromatography-mass spectrometry (LC-

MS) following established methods[35,36] and are expressed as nanograms per gram of tissue. The

metabolic ratio for each enzymatic reaction was calculated by dividing the metabolite

concentration by the precursor concentration.

Sequence data deposition in a public database

Sequencing data were deposited in the Gene Expression Omnibus (GEO): bulk spleen RNA-seq

(GSE303957), bulk RNA-seq of sorted NR5A1-positive cells (GSE303956), and scRNA-seq of

sorted NR5A1-positive cells (GSE303958).

Statistical analyses

At least three animals were used per group unless otherwise specified. Data are presented as the

mean ± SEM. Two-group comparisons were performed using two-tailed Student's *t*-test, and

multiple group comparisons by one-way ANOVA followed by Tukey–Kramer post hoc test; $p <$

0.05 was considered statistically significant.

Results

Spatial heterogeneity of NR5A1-expressing endothelial cells in the spleen

NR5A1 is expressed in the splenic vascular endothelial cells[13], but its distribution in adult spleens has not been thoroughly investigated. We therefore analyzed EGFP expression in Ad4BP-BAC-EGFP mice[15], which faithfully recapitulate endogenous NR5A1 expression. EGFP showed a macroscopically heterogeneous pattern, with strong signals in the red pulp (Fig. 1A, A'). Immunostaining confirmed near-complete overlap between EGFP and endogenous NR5A1 (Fig. S1). Co-staining with CD3ε and CD45R indicated that EGFP was predominantly expressed in endothelial cells of splenic sinusoids in the red pulp (Fig. 1B, C).

To further localize EGFP-positive cells, we compared EGFP expression with macrophage markers (F4/80, MARCO, and CD169) and a marker for marginal sinus-lining cells (mucosal vascular addressin cell adhesion molecule-1 [MAdCAM-1][37]). EGFP was detected adjacent to F4/80-positive macrophages in the red pulp (Fig. 1D-D'') and in the marginal zone containing MARCO-positive macrophages (Fig. 1E-E''). CD169-positive metallophilic macrophages flanked the marginal sinus[7], consistent with EGFP expression in marginal sinus endothelial cells (Fig. 1F-F''). MAdCAM-1 was detected in thin cells closely associated with EGFP-positive cells (Fig. 1G-G'', Fig. S2). Together, these results demonstrate that NR5A1 is expressed in endothelial cells of both the splenic and marginal sinuses. Figure 1H summarizes the schematic representation of spatial distribution of NR5A1-positive cells and other cell types in the marginal sinus and marginal zone.

Functional differences between endothelial cells of the splenic sinus and marginal sinus

We performed scRNA-seq on EGFP-positive cells isolated from Ad4BP-BAC-EGFP spleens. Dimensional reduction and clustering of cells from three mice (two males and one female) yielded highly similar patterns across samples (Fig. S3A) and identified six clusters, including two major populations (clusters 1 and 2; Fig. 2A). *Egfp*, *Nr5a1*, and the sinusoidal endothelial marker *Stab2* were broadly detected, confirming dataset validity (Fig. S3B-D).

To assign anatomical identities, we focused on *Star* and *Cd34*, enriched in clusters 1 and 2, respectively (Fig. 2B, C). Immunostaining of Ad4BP-BAC-EGFP spleens showed marginal sinus-selective localization of CD34 (Fig. 2D). Meanwhile, Immunostaining of StAR/eGFP spleens revealed that StAR-positive cells were largely CD34-negative (Fig. 2E), localized outside the marginal zone (Fig. 2F), and enriched in the red pulp near F4/80-positive

macrophages (Fig. 2G). Thus, clusters 1 and 2 correspond to splenic sinus and marginal sinus

endothelial cells, respectively.

Although canonical endothelial markers (*Pecam1*, *Cdh5*, *Eng*, and *Erg*) were

detected in all clusters (Fig. S3E), GO analysis of the DEGs revealed distinct transcriptional

programs in each cluster (Fig. 2H, Fig. S4; Supplemental Table 3). Cluster 1 was enriched for

genes associated with negative chemotaxis and vascular guidance (*Flrt2*, *Sema3d*, *Robo2*, *Itga9*,

Mmp28) and extracellular matrix organization (*Adamts5*, *Col23a1*) (Fig. 2H, I, Fig. S3F). In

addition, several genes enriched in cluster 1 encode guidance molecules or regulators of

endothelial fate, including *Jag1* and *Gli3*, and factors involved in matrix remodeling and

vasculogenic patterning[38]. In contrast, cluster 2 showed enrichment for genes linked to

endothelial migration and angiogenesis (*Ptp4a3*, *Dll4*, *Col18a1*, *Kdr*, *Id1*, *Adamts9*, *Amotl2*,

Esm1, *Mcam*, *Emcn*) (Fig. 2H, J, Fig. S3G), including markers of endothelial tip cell markers;

Esm1, *Dll4*, *Kdr*, and *Id1*[39-42], and genes mediating cell–cell and cell–matrix interactions; *Esam*,

Col18a1, *Adamts9*, and *Mcam*[43] (Fig. 2J, Fig. S3G), indicating active angiogenic remodeling in

marginal sinus.

Among the minor clusters, cluster 3 was enriched for ribosomal genes, suggesting

low-quality cells; cluster 4 exhibited intermediate profile between clusters 1 and 2; Cluster 5

was enriched for mitotic genes, consistent with proliferating cells; and cluster 6 expressed

markers of neutrophils and lymphocytes (*Ikzf1*, *Igkc*, *Ly6d*), consistent with doublets or

contamination (Fig. 2H, Fig. S3H, Fig. S4).

Identification of the SpE in the Nr5a1 gene

We previously identified multiple tissue-specific enhancers within the *Nr5a1* locus[44-47] (Fig.

3A), and demonstrated the functional importance of each enhancer by deleting it from the

mouse genome[25,26]. Given the high degree of conservation in enhancer regions, we focused on a

conserved sequence within the fourth intron and generated mice with 441-bp deletion by

CRISPR/Cas9 (Fig. 3A, B, Fig. S5), resulting in complete loss of NR5A1 expression in the

spleen (Fig. 3C). We designated this region the spleen enhancer (SpE) and homozygous mutants

as ΔSpE mice.

Heterozygous deletion had no gross effect on spleen size, whereas ΔSpE mice

exhibited marked size reductions (Fig. 3D). Because spleens exhibit sex differences in size and

weight[48], analyses were conducted in both sexes. These analyses revealed a significant reduction

in spleen weight in ΔSpE mice compared with wild type (WT) (Fig. 3E). In contrast, adrenal

glands and gonads were unaffected (Fig. S6), indicating spleen-specific activity of SpE.

Structural and functional abnormality in ΔSpE spleens

H&E staining showed island-like white pulp embedded in red pulp in WT spleens, whereas

ΔSpE exhibited centrally fused white pulp surrounded by a thin layer of red pulp (Fig. 4A). The

white pulp-to-red pulp ratio increased only in female ΔSpE mice (Fig. 4B). WT spleens

displayed a well-defined marginal zone and marginal sinus (Fig. 4C), whereas both structures

were absent in ΔSpE mice (Fig. 4D).

Immunostaining revealed that, in ΔSpE spleens, segregation of B and T cells was

largely preserved; however, neither the marginal zone nor the laminin-positive marginal sinuses

were detectable (Fig. 4E, F). Notably, MARCO- and CD169-positive macrophages were

partially disrupted in heterozygote and absent in ΔSpE spleens (Fig. 4G–I). In addition, flow

cytometry analyses revealed reduced CD21^{hi}/CD23$^{low/-}$ marginal zone B cells[8] and transitional B

cells of type 1 (T1B), whereas other immune cell populations were unaffected (Fig. S7).

Together, these findings demonstrate that SpE-mediated *Nr5a1* expression is

required for formation of the marginal sinus and marginal zone.

Decreased steroidogenic activity in ΔSpE spleen

Bulk RNA-seq of WT and ΔSpE spleens as well as EGFP-positive cells (splenic endothelial

cells; SECs) isolated by FACS from Ad4BP-BAC-EGFP mice was performed to

comprehensively explore the functional changes in ΔSpE spleens. Comparison of WT and ΔSpE

spleens revealed a greater number of downregulated genes in females than in males (1,059 vs.

552 genes), prompting sex-stratified analyses. Among SEC-enriched genes downregulated in

ΔSpE spleens (159 in males and 132 in females), 88 genes were shared between the sexes (Fig.

5A, B; Supplemental Table 4). These shared genes were enriched for GO terms associated with

adrenal hormone biosynthesis pathways (Fig. S8), including *Star* and *Cyp21a1* (Fig. 5C-E).

We focused on CYP21A1, an enzyme essential for adrenocortical steroid hormone

production and confirmed that *Cyp21a1* expression was nearly abolished in ΔSpE spleens (Fig.

5E). LC-MS demonstrated reduced conversion of progesterone to 11-deoxycorticosterone in

ΔSpE spleens, with a strong effect in females (Fig. 5F; Fig. S9A). Single-cell data confirmed

expression of *Star* and *Cyp21a1* in splenic sinus endothelial cells, whereas other steroidogenic

enzymes were minimally or not expressed (Fig. 5G, Fig. S9B). Collectively, these findings

indicate that splenic sinus endothelial cells possess partial steroidogenic capacity, and that this

capacity is dependent on NR5A1.

Lymph node-like structures and fibrosis in ΔSpE spleens

Genes upregulated in ΔSpE spleens were compared between males and females (798 in males

and 726 in females) (Fig. 6A, 6B) and GO analyses of the genes shared between sexes (427

genes in Supplemental Table 5) revealed enrichment for cell migration and lumen formation

(Fig. S10). Notably, the gene set included the lymphatic marker *Lyve1* and HEV-associated

genes *Glycam1* and *Emcn* (Fig. 6C, D). Immunostaining revealed that LYVE-1- and MECA79-

positive structures were almost absent in WT spleens, partially developed in heterozygotes, and

clearly detectable in ΔSpE spleens, as well as in mesenteric lymph nodes (Fig. 6E–H).

MAdCAM-1 was expressed in marginal sinus-lining cells in WT spleens but was weakly

detectable in the red pulp of heterozygotes. In ΔSpE spleens, MAdCAM-1-positive vessels were

well developed in the red pulp and closely resembled HEVs in mesenteric lymph nodes (Fig.

6I–L).

Scanning electron microscopy revealed replacement of fenestrated sinusoids by tall

HEV-like vessels (Fig. 6M, N), accompanied by an increased number of abnormal erythrocytes,

including Howell–Jolly bodies, in the peripheral blood (Fig. S11). Upregulated genes in ΔSpE

spleens were also enriched for extracellular matrix organization and elastic fiber formation (Fig.

S10), and immunostaining confirmed increased laminin-encased vessels and reduced red pulp

macrophages (Fig. S12).

NKX2.3 regulates Nr5a1 expression via direct binding to the SpE

Within the SpE, we identified several small subregions with sequences conserved across

mammalian species (Fig. S5B). One of these subregions, designated R2, contained a predicted

NKX2.3-binding motif (Fig. 7A). Mutation of this site (SpE-R2m; Fig. 7B) resulted in reduced

spleen size, complete loss of NR5A1 expression, absence of the marginal sinus and marginal

zone, and the development of ectopic lymphatic- and HEV-like structures (Fig. 7C–K), closely

resembling the phenotypes of ΔSpE mice.

Nkx2.3 knockout mice exhibit similar phenotypes[20,21,49], and our scRNA-seq data

showed *Nkx2.3* is expressed in splenic and marginal sinus endothelial cells, independent of

NR5A1 deletion (Fig. S13). Together, these results demonstrate that NKX2.3 directly regulates

Nr5a1 expression through the SpE in splenic endothelial cells.

Discussion

NR5A1 defines functionally distinct endothelial populations in the splenic sinus and

marginal sinus

The spleen performs two tightly coupled vascular functions: filtration of circulating blood and

initiation of immune responses. These functions are spatially segregated and associated with the

splenic[1] and marginal sinuses[3,8,9,11,50,51], respectively. Our single-cell transcriptomic analyses

resolved NR5A1-positive endothelial cells into two clusters corresponding to their anatomical

localization. Marginal sinus endothelial cells were enriched for genes involved in vascular

patterning and ECM remodeling, whereas splenic sinus endothelial cells preferentially

expressed genes linked to angiogenesis and cell–substrate adhesion. Notably, marginal sinus

endothelial cells expressed higher levels of *Cd34*, a marker of immature or progenitor-like

endothelial states[52], suggesting that they are less differentiated than splenic sinus endothelial

cells. Together, these data indicate that NR5A1 marks heterogeneous endothelial populations

with compartment-specific transcriptional programs. Defining their developmental relationship

will be an important subject of future studies.

NR5A1-dependent gene programs shape splenic vascular architecture and steroidogenic

capacity

Deletion of the SpE caused marked disruption of splenic architecture, including loss of the

marginal sinus and marginal zone, indicating that NR5A1 is required for morphological

differentiation of spleen-specific vasculature. In addition, ΔSpE spleens showed reduced

expression of *Star* and *Cyp21a1*, key enzymes in adrenal steroidogenesis. Given NR5A1's

established role in regulating these genes in adrenocortical cells, it is likely that NR5A1

similarly controls their expression in splenic sinus endothelial cells.

Although additional enzymes required for complete adrenal steroidogenesis were not

detected in NR5A1-positive splenic cells, adrenal-type steroids were present in whole-spleen

extracts, suggesting cooperation between NR5A1-positive endothelial cells and other splenic

cell types. To our knowledge, this represents the first evidence of adrenal-type steroid hormone

production in the spleen, although its physiological significance remains unclear.

The severe vascular disorganization in ΔSpE mice further indicates that NR5A1

regulates downstream gene networks beyond steroidogenesis. Single-cell analyses suggest that

Star and *Cyp21a1* are selectively regulated by NR5A1 in splenic sinus endothelial cells,

whereas NR5A1 targets in marginal sinus endothelial cells remain undefined. Because the

marginal zone provides a microenvironment for macrophages and B cells essential for immune surveillance of blood-borne antigens, defective marginal sinus formation likely disrupts immune organization. Thus, NR5A1 coordinates both the structural and functional specialization of spleen-specific vasculature.

Sex-specific differences were also evident. Loss of NR5A1 activity produced more pronounced phenotypes in females, including a greater reduction in CYP21A1 expression and altered white pulp–to–red pulp ratios. These findings suggest that NR5A1-dependent vascular and steroidogenic programs are modulated in a sex-dependent manner, potentially reflecting differences in baseline expression, developmental timing, or interactions with sex hormone signaling. Sex differences in immune function are well established in mice and humans[53], and because circulating adrenal steroid hormone levels also show sexual dimorphism, spleen-derived adrenal-type steroid production may contribute to these differences and possibly to immune-related pathologies.

An Nkx2.3–Nr5a1 enhancer axis quantitatively controls spleen-specific vascular development

Although the spleen shares features with other secondary lymphoid organs, NR5A1 expression was restricted to the spleen and absent from lymph nodes and gut-associated lymphoid tissue. We further demonstrate that NKX2.3 binding to the SpE is indispensable for splenic NR5A1 expression, thereby establishing an *Nkx2.3→Nr5a1* regulatory axis that underlies spleen-specific endothelial differentiation.

The mechanism conferring spleen specificity to the SpE remains unresolved. Sequences outside the NKX2.3-binding region may contribute to this specificity, and additional regulatory elements within the *Nr5a1* locus, including potential shadow enhancers, may modulate expression robustness. Moreover, previous work implicating Polycomb group proteins in *Nr5a1* regulation[54] suggests that chromatin-based mechanisms cooperate with the SpE to fine-tune NR5A1 expression.

Our analysis further demonstrates that *Nr5a1* expression is dosage sensitive. Heterozygous SpE deletion or mutation resulted in a much milder phenotype than homozygous deletion, indicating that NR5A1 levels quantitatively regulate spleen development. This dose dependence is consistent with previous reports linking NR5A1 dosage to cell differentiation and tissue morphogenesis[55] and likely reflects enhancer redundancy, whereby loss of a single enhancer produces a weaker phenotype than homozygous deletion[56]. Clinically, NR5A1

haploinsufficiency causes variable adrenal and gonadal phenotypes in humans[57,58]. Our findings

extend this concept to the spleen, showing that even modest reductions in NR5A1 perturb

vascular organization and reinforcing the principle that transcription factor dosage quantitatively

shapes organ development.

Acknowledgements

We appreciate the technical support provided by the Central Research Center, Kawasaki

Medical School, and the Institute for Disease Modeling, Kurume University School of

Medicine. We also thank the organizers of the Medical Research Center at Saitama Medical

University for providing continuous support throughout this study. This study was supported by

the Research Program for the Inter-University Research Network for High-Depth Omics,

IMEG, Kumamoto University, Japan. This work was supported in part by the MEXT Promotion

of Development of a Joint Usage/Research System Project: Pan-Omics DDRIC, MRCI for

High-Depth Omics, CURE: JPMXP1323015486 for MIB, RIIT, and the Autonomous Medical

Research Center at Kyushu University. We would like to thank Editage (www.editage.jp) for

English language editing.

Author contributions

Conceptualization, Y. S.; Investigation, K. M., K. O., Miki Inoue, T. S., A. Y., Masanori Iseki,

Katsuhiko Ishihara, T. M., R. S., Kei-ichirou Ishiguro, J. N., M. H. C., T. B., Y. O., E. K., K. T.,

and Y. S.; Resources, T. I.; Format analysis and Writing – Original Draft Preparation, K. M.,

K.O., and Y. S.; Writing – Review & Editing, T. S., A. Y., Masanori Iseki, Katsuhiko Ishihara,

T. M., Miki Inoue, R. S., Kei-ichirou Ishiguro, M. H. C., T. B., Y. O., E. K., K. T., and Y. S.;

Funding Acquisition, K. M., K. O., Y. S., and Supervision, Y. S.

Competing interests

The authors have no conflicts of interest to disclose.

 Figure Legends

Figure 1. **EGFP expression in the spleen of Ad4BP-BAC-EGFP mice.**

(A, A') Macroscopic view of WT and Ad4BP-BAC-EGFP mouse spleens under bright-field (A)

and EGFP fluorescence (A') microscopy. The WT spleen is outlined with a white dotted line in

A'. Bar = 500 µm.

(B, C) Immunostaining for EGFP together with CD3ε and CD45R in Ad4BP-BAC-EGFP

mouse spleens, shown with (B) or without (C) DAPI nuclear counterstaining. Bar = 100 µm.

(D-D'', E-E'', F-F'', G-G'') Immunostaining of EGFP with cell type-specific markers: F4/80

(D-D''), MARCO (E-E''), CD169 (F-F''), and MAdCAM-1 (G-G''). Arrows indicate EGFP

expression in the endothelial cells of the venous sinuses in the red pulp (splenic sinuses), and

arrowheads indicate EGFP expression in the endothelial cells of the venous sinuses at the border

between the white pulp and the marginal zone (marginal sinuses). Bar = 50 µm.

(H) Schematic illustration of the histological structure of the marginal zone and marginal sinus,

showing the cell types observed in this region. RP, red pulp; WP, white pulp.

Figure 2. **Functional and spatial heterogeneity of EGFP-positive endothelial cells in the**

spleens of Ad4BP-BAC-EGFP mice.

(A) UMAP plot of clusters consisting of EGFP-positive endothelial cells isolated from Ad4BP-

BAC-EGFP spleens.

(B–C) Feature plots of representative genes expressed in EGFP-positive endothelial cells: *Star*

(B) and *Cd34* (C).

(D) Immunostaining of EGFP and CD34 in Ad4BP-BAC-EGFP spleens. Arrows indicate

CD34/EGFP double-positive cells.

(E-G) Immunostaining of EGFP with CD34 (H), MARCO (I), or F4/80 (J) in StAR/eGFP

spleens. Arrows in (E) indicate small number of CD34/EGFP double-positive cells in

StAR/eGFP spleens. Bar = 100 µm. RP, red pulp; WP, white pulp.

(H) Bubble plot showing the biological processes characterizing each cluster. The top 150

highly expressed genes in each cluster were used for GO analysis.

(I) Feature plots of representative genes highly expressed in cluster 1: *Flrt2*, *Sema3d*, *Adamts5*,

Ccbe1, *Itga9*, and *Jag1*.

(J) Feature plots of representative genes highly expressed in cluster 2: *Ptp4a3*, *Dll4*, *Kdr*,

Adamts9, *Esm1*, and *Esam*.

Figure 3. **Spleen-specific depletion of NR5A1 by deletion of the spleen enhancer (SpE) of**

the *Nr5a1* gene.

(A) Schematic representation of the *Nr5a1* gene structure and sequence conservation among

mammals. Gray boxes indicate previously identified enhancers, including fetal Leydig enhancer

(FLE), fetal adrenal enhancer (FAdE), ventromedial hypothalamus enhancer (VE), and pituitary

enhancer (PE). The yellow box indicates the spleen enhancer (SpE) located in intron 4. Arrows

(SpE-Fw and SpE-Re) denote genotyping primers.

(B) PCR-based genotyping of SpE-deleted mice. The WT allele yields a 655-bp fragment,

whereas the SpE-deleted allele yields a 213-bp fragment.

(C) Loss of NR5A1 expression in the spleens of △SpE mice. Western blot analysis of NR5A1

and LaminB1 in nuclear extracts from spleens of WT (+/+), heterozygous (+/-), and

homozygous (-/-) SpE-deleted mice.

(D) Gross morphology of spleens from WT, heterozygote (Het), and △SpE mice.

(E) Spleen weight-to-body weight ratio in each genotype and sex (mean ± SE). Sample size:

male WT, n = 12; male △SpE, n = 6; female WT n = 9; female △SpE, n = 5. $p < 0.01$ (**).

Figure 4. **Morphological analysis of △SpE spleens.**

(A) Hematoxylin and eosin (H&E) staining of spleens from each genotype and sex. Scale bar =

2 mm

(B) White pulp-to-red pulp area ratios in each genotype and sex. Sample sizes: male WT, n = 6;

male △SpE, n = 4; female WT n = 5; female △SpE, n = 3. $p < 0.01$ (**).

(C, D) High-magnification H&E-stained images of WT and △SpE spleens. Arrows indicate

marginal sinuses. Scale bar = 100 μm.

(E, F) Immunostaining of CD45R, CD3ε, and laminin in WT and △SpE spleens. RP, red pulp;

WP, white pulp; MZ, marginal zone. Scale bar = 100 μm.

(G., H., I) Immunostaining for MARCO and CD169 in WT, heterozygote (Het), and △SpE

spleens. Scale bar = 100 μm.

Figure 5. **Downregulated genes in △SpE spleens.**

(A) Schematic representation of the strategy for gene expression analyses. Comparison of gene

expression between WT spleens and sorted NR5A1[+] sinusoidal endothelial cells (SECs)

identified genes enriched in SECs (Up in SEC). Comparison between WT and △SpE spleens

identified genes downregulated in ΔSpE (Down in ΔSpE). Genes included in both categories

(Up in SEC and Down in ΔSpE) were extracted for each sex.

(B) Venn diagram showing overlapping (Up in SEC and Down in ΔSpE) genes in both sexes.

(C) Schematic representation of steroid biosynthetic pathways, including steroidogenic

enzymes, precursors, and metabolites. Enzymes indicated in blue are among 88 genes identified

in (B). Metabolites indicated in red represent corticosteroid hormones and their precursors.

(D) Volcano plot of gene expression in WT and ΔSpE spleens. Genes in red indicate

representative genes downregulated in ΔSpE.

(E) Expression levels of *Cyp21a1* gene in WT and ΔSpE spleens in each sex, showing as counts

per million (CPM). $p < 0.01$ (**).

(F) Metabolic activity of 21α-hydroxylase, assessed by precursor and metabolite concentrations

in WT and △SpE spleens of each sex, determined by liquid chromatography-mass spectrometry

(LC-MS). $p < 0.05$ (*).

(G) Feature plot of *Cyp21a1* expression in a UMAP presentation of NR5A1^{+} endothelial cells in

the spleen.

Figure 6. **Upregulated genes in ΔSpE spleens.**

(A) Schematic representation of the strategy for gene expression analyses. Comparison of gene

expression between WT and △SpE spleens identified genes upregulated in △SpE (Up in △SpE).

(B) Venn diagram showing (Up in △SpE) genes in both sexes.

(C) Volcano plot of gene expression in WT and △SpE spleens. Genes in red indicate

representative genes upregulated in ΔSpE.

(D) Expression levels of *Lyve1*, *Glycam1*, *and Emcn* genes in WT and ΔSpE spleens in each

sex, showing as counts per million (CPM). $p < 0.01$ (**).

(E, F, G, H) Immunostaining of LYVE-1 and MECA79 in WT, heterozygote (Het), △SpE

spleens and WT mesenteric lymph node (WT mLN). Scale bar = 100 μm.

(I, J, K, L) Immunostaining of LYVE-1 and MAdCAM-1 in WT, heterozygote (Het), △SpE

spleens and WT mesenteric lymph node (WT mLN). Scale bar = 100 μm.

(M, N) Scanning electron microscopy (SEM) images of WT and △SpE spleens. Scale bar = 50

μm.

Figure 7. **NKX2.3 regulates *Nr5a1* gene expression in the spleen via direct binding to SpE.**

(A) Schematic representation of a mutation induced in R2 sequence in SpE. The yellow box

indicates SpE, and arrows indicate genotyping primers (SpE-Fw and SpE-Re). The red open

rectangle indicates the R2 sequence, and asterisks indicate the NKX2.3-binding motif. Mutated

R2 sequence (R2m) contains *Bam*HI restriction element (*Bam*HI-RE). The consensus sequence

for human NKX2-3 binding was searched in JASPAR (https://jaspar.genereg.net/) and is shown

in PWM format.

(B) PCR-based genotyping of SpE-R2m mice. The WT allele yielded a 655-bp fragment,

whereas the SpE-R2m allele yielded 429-bp and 225-bp fragments.

(C) Gross morphology of spleens from WT (+/+) and homozygous mutation in SpE (SpE-R2m)

mice. Scale bar = 2 mm.

(D, E) Immunostaining of NR5A1 in WT and SpE-R2m spleens. Scale bar = 50 μm.

(F, G, H) Immunostaining of CD34 and MARCO in WT, heterozygote (Het) and SpE-R2m

spleens. Scale bar = 100 μm.

(I, J, K) Immunostaining of CD34 and MARCO in WT, heterozygote (Het), and SpE-R2m

spleens. Scale bar = 100 μm.

Supplemental Figure 1. **Comparison of endogenous NR5A1 and EGFP expression in the**

spleens of Ad4BP-BAC-EGFP mice.

Double immunostaining for NR5A1 (red) and EGFP (green) and nuclear counterstaining with

DAPI (blue) were performed on spleen sections from Ad4BP-BAC-EGFP mice. Images of the

same field are as follows: (A) NR5A1 channel; (B) EGFP channel; (C) merged NR5A1 and

EGFP; and (D) merged NR5A1, EGFP, and DAPI. Magnified views of the regions including the

marginal sinus are presented as A', B', C', and D', with arrowheads indicating endothelial cells

of the marginal sinus. Likewise, enlarged views of regions including the splenic sinus are shown

as A'', B'', C'', and D'', with arrows indicating the endothelial cells of the splenic sinus. Scale

bar = 50 µm.

Supplemental Figure 2 **Spatial relationship between EGFP-positive cells and MAdCAM-1-**

positive cells in the spleen of Ad4BP-BAC-EGFP mice.

(A) Immunofluorescence image of MAdCAM-1, EGFP, and Laminin, together with DAPI

nuclear staining, in the spleens of Ad4BP-BAC-EGFP mice. The region outlined by the yellow

box is shown enlarged in panel B. Scale bar = 50 µm The image in panel B is further separated

into individual channels: MAdCAM-1 (red) in panel C; laminin (white) in panel D; merged

MAdCAM-1 and EGFP in panel E; EGFP (green) in panel F; and DAPI (blue) in panel G.

Dotted lines in panels C, D, F, and G indicate MAdCAM-1-positive cells. (H) Line plot

generated along the direction indicated by the arrow in Panel B. The plot shows that EGFP-

positive cells (green) are adjacent to MAdCAM-1-positive cells (red). Scale bar = 10 µm

Supplemental Figure 3. **Gene expression profiles in each cluster of NR5A1+ cells in the**

spleens of Ad4BP-BAC-EGFP mice.

(A) UMAP plot of cells from three mice (two males and one female) after merging the datasets,

with cells colored according to their individual origin.

(B–D) Feature plots of representative genes expressed in EGFP-positive endothelial cells: *Egfp*

(B), *Nr5a1* (C), *Stab2* (D).

(E) Feature plots of representative genes commonly expressed in clusters 1 and 2.

(F) Feature plots of representative genes that were highly expressed in cluster 1.

(G) Feature plots of representative genes highly expressed in cluster 2.

(H) Feature plots of representative genes highly expressed in cluster 6 (highlighted with red

circles).

Supplemental Figure 4. **GO analysis of genes enriched in each cluster of NR5A1$^+$ sinus**

endothelial cells in the spleens of Ad4BP-BAC-EGFP mice.

(A) Bubble plot showing the molecular functions associated with each cluster identified by

scRNA-seq in EGFP$^+$ sinus endothelial cells. (B) Bubble plot showing the cellular components

associated with each cluster identified by scRNA-seq of EGFP$^+$ sinus endothelial cells. Gene

Ontology (GO) analysis was performed using the top 150 highly expressed genes in each

cluster.

Supplemental Figure 5. **Schematic illustration of the SpE deletion by CRISPR/Cas9.**

(A) Two guide RNAs were designed to target the upstream and downstream regions of the SpE.

Arrows (SpE-Fw and SpE-Re) indicate the positions of the genotyping PCR primers. Nucleotide

sequences surrounding the guide RNA target sites are shown (WT, wild type; del, SpE

deletion). Guide RNA target sequences are shown in red, and PAM sequences are underlined.

(B) Alignment of the nucleotide sequences of SpE regions in mice, rats, rabbits, pigs, and dogs

using MAFFT (https://mafft.cbrc.jp/alignment/software/). Asterisks indicate nucleotides

conserved among all species. Guide RNA target sequences are shown in red, and PAM

sequences are underlined. Nucleotides boxed in red indicate the R2 sequence, the mutation of

which abolished enhancer activity.

Supplemental Figure 6. **Morphology of NR5A1-expressing organs other than the spleen in**

ΔSpE mice.

(A) Gross morphology of the adrenal glands in WT and ΔSpE mice.

(B) Gross morphology of the ovaries in WT and ΔSpE mice.

(C) Gross morphology of the testes in WT and ΔSpE mice.

Scale bar = 2 mm.

Supplemental Figure 7. **Flow cytometry analysis of splenic immune cells in ΔSpE mice.**

(A) Representative flow cytometry plot of the spleen. B: B cells (CD19$^+$), MZB: marginal zone

B cells (CD19$^+$CD21/35^{high}CD23$^{low/-}$), FoB: follicular B cells (CD19$^+$CD21/35^{high}CD23^{high}),

T1B: Transitional B cells of type1 (CD19$^+$CD21/35$^-$CD23$^-$), T2B: transitional B cells of type 2

(CD19$^+$CD23$^+$CD21/35$^+$IgM$^+$).

(B) Flow cytometry of B-cell subsets isolated from the spleen of a WT mouse.

CD21/35^{high}CD23$^{low/-}$ (marginal zone B cells) cells constitute 6.91% of CD19$^+$ B cells.

(C) Flow cytometry of B-cell subsets isolated from the spleen of an SpE heterozygous mouse.

CD21/35^{high}CD23$^{low/-}$ cells constitute 7.38% of CD19$^+$B cells.

(D) Flow cytometry analysis of B-cell subsets isolated from the spleen of a ΔSpE mouse.

CD21/35^{high}CD23$^{low/-}$ cells constituted 0.66% of CD19$^+$B cells.

(E) Frequencies of B-cell subsets in the spleen: B: B cells, FoB: follicular B cells, T1B:

transitional B cells of type 1, T2B: transitional B cells of type 2, MZB: marginal zone B cells,

WT: wild-type: Het, heterozygous deletion of SpE, ΔSpE: deletion of SpE,*: $p < 0.05$, ns: not

significant.

Supplemental Figure 8. **GO analysis of genes downregulated in the spleens of ΔSpE mice.**

(A) Biological processes associated with the downregulated genes in ΔSpE spleens.

(B) Tissue specificity of genes downregulated in ΔSpE spleens.

(C) Transcription factors predicted to regulate the genes downregulated in ΔSpE spleens.

Supplemental Figure 9. **Steroid levels and expression of steroidogenic genes in the spleen.**

(A) The concentrations of progesterone and 11-deoxycorticosterone were measured by LC-MS.

M, male; F, female; WT, wild type.

(B) Feature plots showing the expression of the genes required for adrenal steroid production.

Star and *Cyp21a1* were expressed in cluster 1, whereas the expression of the other genes was

very low or undetectable (ND).

Supplemental Figure 10. **Upregulated genes in the spleens of ΔSpE mice.**

Biological processes identified by GO analysis of genes upregulated in the spleen of ΔSpE

mice.

Supplemental Figure 11. **Abnormal peripheral erythrocytes in ΔSpE mice.**

(A) Giemsa-stained peripheral blood samples from control male mouse.

(B) Giemsa-stained peripheral blood samples from a male ΔSpE mice. Arrows indicate

abnormal erythrocytes containing Howell–Jolly bodies. Scale bar = 20 μm.

(C) The proportion of erythrocytes containing Howell–Jolly bodies in control and ΔSpE mice of

each sex. At least 1,000 erythrocytes were examined per specimen (n = 4). $p < 0.01$ (**).

Supplemental Figure 12. **Increased ECM expression in the spleens of ΔSpE mice.**

(A–C) Double immunostaining for F4/80 (red) and Laminin (green) with nuclear

counterstaining using DAPI (blue) in the spleen sections. WT, wild type; Het, SpE

heterozygous. Scale bar = 100 µm.

Supplemental Figure 13. *Nkx2-3* **expression in the spleens of ΔSpE mice.**

(A) Feature plot showing *Nkx2-3* expression in NR5A1$^+$ cells isolated from the spleens of

Ad4BP-BAC-EGFP mice. *Nkx2-3* is expressed in clusters 1 and 2.

(B) *Nkx2-3* expression in the spleens of WT and ΔSpE mice of both sexes, as revealed by

mRNA-sequence analysis. Expression levels are expressed as counts per million (CPM).

References

1.　MacDonald IC, Ragan DM, Schmidt EE, Groom AC. Kinetics of red blood cell passage
through interendothelial slits into venous sinuses in rat spleen, analyzed by in vivo
microscopy. *Microvasc Res*. 1987;33(1):118-134.

2.　Bratosin D, Mazurier J, Tissier JP, et al. Cellular and molecular mechanisms of senescent
erythrocyte phagocytosis by macrophages. A review. *Biochimie*. 1998;80(2):173-195.

3.　Mebius RE, Kraal G. Structure and function of the spleen. *Nat Rev Immunol*. 2005;5(8):606-
616.

4.　Geijtenbeek TB, Groot PC, Nolte MA, et al. Marginal zone macrophages express a murine
homologue of DC-SIGN that captures blood-borne antigens in vivo. *Blood*.
2002;100(8):2908-2916.

5.　Elomaa O, Kangas M, Sahlberg C, et al. Cloning of a novel bacteria-binding receptor
structurally related to scavenger receptors and expressed in a subset of macrophages. *Cell*.
1995;80(4):603-609.

6.　Kraal G, Janse M. Marginal metallophilic cells of the mouse spleen identified by a
monoclonal antibody. *Immunology*. 1986;58(4):665-669.

7.　Munday J, Floyd H, Crocker PR. Sialic acid binding receptors (siglecs) expressed by
macrophages. *J Leukoc Biol*. 1999;66(5):705-711.

8.　Martin F, Kearney JF. Marginal-zone B cells. *Nat Rev Immunol*. 2002;2(5):323-335.

9.　Borges da Silva H, Fonseca R, Pereira RM, Cassado Ados A, Alvarez JM, D'Imperio Lima
MR. Splenic macrophage subsets and their function during blood-borne infections. *Front
Immunol*. 2015;6:480.

10.　Koppel EA, Litjens M, van den Berg VC, van Kooyk Y, Geijtenbeek TB. Interaction of
SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to
early IgM responses against Streptococcus pneumoniae. *Mol Immunol*. 2008;45(10):2881-
2887.

11.　Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. *Immunity*.
2013;39(5):806-818.

12.　Parker KL, Schimmer BP. Steroidogenic factor 1: a key determinant of endocrine
development and function. *Endocr Rev*. 1997;18(3):361-377.

13.　Morohashi K, Tsuboi-Asai H, Matsushita S, et al. Structural and functional abnormalities in
the spleen of an mFtz-F1 gene-disrupted mouse. *Blood*. 1999;93(5):1586-1594.

14. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and
gonadal development and sexual differentiation. *Cell*. 1994;77(4):481-490.

15. Kalucka J, de Rooij L, Goveia J, et al. Single-cell transcriptome atlas of murine endothelial
cells. *Cell*. 2020;180(4):764-779 e720.

16. Morohashi KI, Omura T. Ad4BP/SF-1, a transcription factor essential for the transcription
of steroidogenic cytochrome P450 genes and for the establishment of the reproductive
function. *FASEB J*. 1996;10(14):1569-1577.

17. Pabst O, Zweigerdt R, Arnold HH. Targeted disruption of the homeobox transcription factor
Nkx2-3 in mice results in postnatal lethality and abnormal development of small intestine
and spleen. *Development*. 1999;126(10):2215-2225.

18. Wang CC, Biben C, Robb L, et al. Homeodomain factor Nkx2-3 controls regional expression
of leukocyte homing coreceptor MAdCAM-1 in specialized endothelial cells of the viscera.
Dev Biol. 2000;224(2):152-167.

19. Tarlinton D, Light A, Metcalf D, Harvey RP, Robb L. Architectural defects in the spleens of
Nkx2-3-deficient mice are intrinsic and associated with defects in both B cell maturation and
T cell-dependent immune responses. *J Immunol*. 2003;170(8):4002-4010.

20. Kellermayer Z, Labadi A, Czompoly T, Arnold HH, Balogh P. Absence of Nkx2-3
homeodomain transcription factor induces the formation of LYVE-1-positive endothelial
cysts without lymphatic commitment in the spleen. *J Histochem Cytochem*. 2011;59(7):690-
700.

21. Gabris F, Kiss G, Szirmay B, et al. Absence of Nkx2-3 induces ectopic lymphatic endothelial
differentiation associated with impaired extramedullary stress hematopoiesis in the spleen.
Front Cell Dev Biol. 2023;11:1170389.

22. Miyabayashi K, Tokunaga K, Otake H, Baba T, Shima Y, Morohashi K. Heterogeneity of
ovarian theca and interstitial gland cells in mice. *PLoS One*. 2015;10(6):e0128352.

23. Sasaki G, Ishii T, Jeyasuria P, et al. Complex role of the mitochondrial targeting signal in the
function of steroidogenic acute regulatory protein revealed by bacterial artificial
chromosome transgenesis in vivo. *Mol Endocrinol*. 2008;22(4):951-964.

24. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable
dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*.
2012;337(6096):816-821.

25. Shima Y, Miyabayashi K, Mori T, et al. Intronic enhancer is essential for Nr5a1 expression
in the pituitary gonadotrope and for postnatal development of male reproductive organs in a

mouse model. *Int J Mol Sci*. 2022;24(1):192.

26. Shima Y, Miyabayashi K, Sato T, et al. Fetal Leydig cells dedifferentiate and serve as adult

Leydig stem cells. *Development*. 2018;145(23):dev169136.

27. Hao Y, Stuart T, Kowalski MH, et al. Dictionary learning for integrative, multimodal and

scalable single-cell analysis. *Nat Biotechnol*. 2024;42(2):293-304.

28. McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet detection in single-cell

RNA sequencing data using artificial nearest neighbors. *Cell Syst*. 2019;8(4):329-337 e324.

29. Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell

data with Harmony. *Nat Methods*. 2019;16(12):1289-1296.

30. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting

omics data. *Innovation (Camb)*. 2021;2(3):100141.

31. Gamliel H, Golomb HM, Avinoah E, Gurfel D, Polliack A. Topical modes in the preparation

of human spleen specimens for routine scanning electron microscopy studies. *Scan Electron*

Microsc. 1986;Pt 3(Pt 3):1039-1050.

32. Fujita T. A scanning electron microscope study of the human spleen. *Arch Histol Jpn*.

1974;37(3):187-216.

33. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the

analysis of systems-level datasets. *Nat Commun*. 2019;10(1):1523.

34. Yahagi A, Iseki M, Yaku K, et al. Aberrant humoral immune responses and intestinal

homeostasis in Cd38 Bst1 double knockout mice. *Immunohorizons*. 2025;9(8):vlaf029.

35. Han S, Baba T, Yanai S, et al. GC-MS-based metabolic signatures reveal comparative

steroidogenic pathways between fetal and adult mouse testes. *Andrology*. 2021;9(1):400-406.

36. Noh J, Lee C, Kim JH, Myung SW, Choi MH. LC-MS based simultaneous profiling of

adrenal hormones of steroids, catecholamines, and metanephrines. *J Lipid Res*.

2023;64(11):100453.

37. Kraal G, Schornagel K, Streeter PR, Holzmann B, Butcher EC. Expression of the mucosal

vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen. *Am J Pathol*.

1995;147(3):763-771.

38. Libby JR, Royce H, Walker SR, Li L. The role of extracellular matrix in angiogenesis:

Beyond adhesion and structure. *Biomater Biosyst*. 2024;15:100097.

39. Goveia J, Rohlenova K, Taverna F, et al. An integrated gene expression landscape profiling

approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates.

Cancer Cell. 2020;37(1):21-36 e13.

40. Geldhof V, de Rooij L, Sokol L, et al. Single cell atlas identifies lipid-processing and
immunomodulatory endothelial cells in healthy and malignant breast. *Nat Commun*.
2022;13(1):5511.

41. Kang B, Camps J, Fan B, et al. Parallel single-cell and bulk transcriptome analyses reveal
key features of the gastric tumor microenvironment. *Genome Biol*. 2022;23(1):265.

42. Zeng Q, Mousa M, Nadukkandy AS, et al. Understanding tumour endothelial cell
heterogeneity and function from single-cell omics. *Nat Rev Cancer*. 2023;23(8):544-564.

43. Francavilla C, Maddaluno L, Cavallaro U. The functional role of cell adhesion molecules in
tumor angiogenesis. *Semin Cancer Biol*. 2009;19(5):298-309.

44. Shima Y, Zubair M, Ishihara S, et al. Ventromedial hypothalamic nucleus-specific enhancer
of Ad4BP/SF-1 gene. *Mol Endocrinol*. 2005;19(11):2812-2823.

45. Zubair M, Ishihara S, Oka S, Okumura K, Morohashi K. Two-step regulation of Ad4BP/SF-
1 gene transcription during fetal adrenal development: initiation by a Hox-Pbx1-Prep1
complex and maintenance via autoregulation by Ad4BP/SF-1. *Mol Cell Biol*.
2006;26(11):4111-4121.

46. Shima Y, Zubair M, Komatsu T, et al. Pituitary homeobox 2 regulates adrenal4 binding
protein/steroidogenic factor-1 gene transcription in the pituitary gonadotrope through
interaction with the intronic enhancer. *Mol Endocrinol*. 2008;22(7):1633-1646.

47. Shima Y, Miyabayashi K, Baba T, et al. Identification of an enhancer in the Ad4BP/SF-1
gene specific for fetal Leydig cells. *Endocrinology*. 2012;153(1):417-425.

48. Menees KB, Earls RH, Chung J, et al. Sex- and age-dependent alterations of splenic immune
cell profile and NK cell phenotypes and function in C57BL/6J mice. *Immun Ageing*.
2021;18(1):3.

49. Czompoly T, Labadi A, Kellermayer Z, Olasz K, Arnold HH, Balogh P. Transcription factor
Nkx2-3 controls the vascular identity and lymphocyte homing in the spleen. *J Immunol*.
2011;186(12):6981-6989.

50. Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the
spleen. *Sci Immunol*. 2019;4(33):eaau6085.

51. Kraal G, Mebius R. New insights into the cell biology of the marginal zone of the spleen. *Int
Rev Cytol*. 2006;250:175-215.

52. Hassanpour M, Salybekov AA, Kobayashi S, Asahara T. CD34 positive cells as endothelial
progenitor cells in biology and medicine. *Front Cell Dev Biol*. 2023;11:1128134.

53. Dunn SE, Perry WA, Klein SL. Mechanisms and consequences of sex differences in immune

responses. *Nat Rev Nephrol*. 2024;20(1):37-55.

54. Katoh-Fukui Y, Owaki A, Toyama Y, et al. Mouse Polycomb M33 is required for splenic

vascular and adrenal gland formation through regulating Ad4BP/SF1 expression. *Blood*.

2005;106(5):1612-1620.

55. Fatchiyah, Zubair M, Shima Y, et al. Differential gene dosage effects of Ad4BP/SF-1 on

target tissue development. *Biochem Biophys Res Commun*. 2006;341(4):1036-1045.

56. Kim S, Wysocka J. Deciphering the multi-scale, quantitative cis-regulatory code. *Mol Cell*.

2023;83(3):373-392.

57. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding

steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. *Nat Genet*.

1999;22(2):125-126.

58. Camats N, Pandey AV, Fernandez-Cancio M, et al. Ten novel mutations in the NR5A1 gene

cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals.

J Clin Endocrinol Metab. 2012;97(7):E1294-1306.

Miyabayashi, et al., Figure 1

Miyabayashi, et al., Figure 2

A

10 kb

Nr5a1 gene

FLE

SpE FAdE

VE PE

2 kb

Ex.4   Ex.5

SpE-Fw   SpE-Re

SpE   FAdE

B

1000 bp
500 bp
200 bp

+/− +/− +/+ −/−

C

Spleen   Adrenal

NR5A1

LaminB1

+/+ +/− −/− +/+ +/− −/−

D

WT   Het   *ΔSpE*

E

Spleen/Body weight (%)

**   **

M (WT) M (*ΔSpE*) F (WT) F (*ΔSpE*)

Miyabayashi, et al., Figure 3

Miyabayashi, et al., Figure 4

Miyabayashi, et al., Figure 5

A Up in *ΔSpE*

WT (♂3, ♀3) ⟷ *ΔSpE* (♂3, ♀3)

B Up in *ΔSpE*

♂ 371 | 427 | ♀ 299

C Up in *ΔSpE* | Up in WT

Glycam1
Lyve1
Emcn

-Log₁₀(p-value)

Log₂(FC)

D

Lyve1 ** **
CPM
WT_male ΔSpE_male WT_female ΔSpE_female

Glycam1 ** **
CPM
WT_male ΔSpE_male WT_female ΔSpE_female

Emcn ** **
CPM
WT_male ΔSpE_male WT_female ΔSpE_female

| WT | Het | *ΔSpE* | WT mLN |

E **F** **G** **H** (LYVE-1 MECA79 DAPI)

I **J** **K** **L** (LYVE-1 MadCAM-1 DAPI)

| WT | *ΔSpE* |

SEM **M** **N**

Miyabayashi, et al., Figure 6

A

SpE-Fw → SpE ← SpE-Re

R2

GGGGCA GGGCACTTCCTCTGG CCGCC

* * * * * * * * *

GGGGCA AAAAAGGATCCAAAA CCGCC

BamHI-RE

Sequence logo

NKX2-3 (Homo sapiens, MA0672.1)

B

— 1000 bp
— 500 bp
— 200 bp

+/+   m/+   m/m   m/m

C

+/+

SpE-R2m

WT   *SpE-R2m*

D NR5A1/DAPI   **E**

WT   Het   *SpE-R2m*

F CD34/MARCO/DAPI   **G**   **H**

I LYVE1/MAdCAM1/DAPI   **J**   **K**

Miyabayashi, et al., Figure 7